Heart failure is one of the most serious and widespread health conditions in the United States and many other countries around the world.
Millions of people are living with this disease, and the number continues to increase as populations age and chronic conditions such as high blood pressure, diabetes, and obesity become more common.
Despite its name, heart failure does not mean that the heart has completely stopped working. Instead, it means that the heart can no longer pump enough blood to meet the body’s needs.
When this happens, organs and tissues may not receive enough oxygen and nutrients. As a result, people often experience symptoms such as fatigue, shortness of breath, weakness, and swelling in the legs, ankles, feet, or abdomen due to fluid buildup.
Heart failure also places a major burden on healthcare systems. It is one of the leading causes of hospital admissions among older adults and contributes billions of dollars in medical costs every year. Because of its widespread impact, researchers have spent decades studying the condition and searching for better treatments.
Many people think of heart failure as a condition in which the heart muscle becomes weak and loses its ability to pump blood effectively. This type is known as heart failure with reduced ejection fraction, often called HFrEF. In this form of the disease, the heart’s pumping strength is lower than normal.
Doctors have developed several treatments that improve survival and reduce symptoms for people with HFrEF. One of the most important groups of medications is known as beta-blockers.
These drugs help slow the heart rate, lower blood pressure, reduce stress on the heart, and control certain abnormal heart rhythms. Numerous studies have shown that beta-blockers can help people with weak-heart heart failure live longer and stay out of the hospital.
However, not all heart failure is caused by a weak heart muscle. Another common form of the disease occurs when the heart becomes stiff rather than weak.
In this condition, the heart still pumps blood with normal strength, but it has difficulty relaxing between beats. Because the heart cannot relax properly, it cannot fill with enough blood before each contraction.
This condition is known as heart failure with preserved ejection fraction, or HFpEF. Some experts describe it as “stiff-heart” heart failure. HFpEF is particularly common in older adults and is frequently seen in people with high blood pressure, diabetes, obesity, and other long-term health conditions.
Treating HFpEF has been challenging. Unlike weak-heart heart failure, there are relatively few treatments that have been proven to significantly improve outcomes. As a result, doctors sometimes prescribe medications that are effective for HFrEF, even though the two forms of heart failure have different underlying causes.
A new study from researchers at the University of Vermont suggests that one commonly used treatment may not benefit people with HFpEF and could potentially worsen their condition. The researchers analyzed data from a major clinical study known as the TOPCAT trial, which followed people with HFpEF over time to better understand their health outcomes.
When the team examined the data, they found that approximately 80 percent of participants were taking beta-blockers. Surprisingly, patients using these medications were significantly more likely to be hospitalized because of worsening heart failure symptoms.
The analysis showed that people taking beta-blockers had a 74 percent higher risk of hospitalization for heart failure compared with participants who were not taking the drugs. This finding raised important questions about whether beta-blockers are always appropriate for patients with the stiff-heart form of the disease.
The researchers believe the explanation may lie in the unique nature of HFpEF. In this condition, the main problem is not poor pumping strength but poor relaxation of the heart muscle. Beta-blockers slow the heart rate and alter pressure inside the heart chambers.
While these effects can be beneficial for patients with weak-heart heart failure, they may have different consequences in people whose hearts are already stiff.
According to the researchers, slowing the heart and changing internal pressures may increase pressure in the heart and lungs for some HFpEF patients. This could contribute to fluid buildup, breathing difficulties, and worsening symptoms that eventually require hospitalization.
The findings do not mean that people with HFpEF should immediately stop taking beta-blockers. Many patients need these medications for other medical reasons, including high blood pressure, irregular heart rhythms, angina, or a history of heart attack. Any medication changes should always be discussed with a healthcare provider.
Instead, the study highlights the importance of understanding that heart failure is not a single disease. Different forms of heart failure may respond differently to treatment. A medication that provides major benefits for one group of patients may not have the same effects in another group.
The researchers say their findings reveal an important gap in current medical knowledge. More research is needed to determine which patients with HFpEF may benefit from beta-blockers and which patients may be better served by alternative treatment approaches.
Future studies could help doctors develop more personalized treatment plans based on the specific type of heart failure a person has.
The study was led by Dr. Timothy Plante and colleagues at the University of Vermont. Their findings were published in the medical journal JAMA Network Open. The researchers hope their work will encourage further investigation into HFpEF and lead to better therapies for the growing number of people affected by this condition.
For patients and families, the study offers an important reminder. Understanding the exact type of heart failure is essential because treatment decisions may differ significantly.
Open discussions with healthcare providers about medications, symptoms, and treatment goals can help ensure that each person receives the most appropriate care for their specific condition.
As scientists continue to learn more about heart failure, research like this may help move medicine closer to a future where treatments are tailored to individual patients rather than applying the same approach to everyone. Such advances could improve quality of life, reduce hospitalizations, and help people with heart failure live healthier and longer lives.
If you care about health, please read studies about the benefits of low-dose lithium supplements, and what we know about egg intake and heart disease.
For more health information, please see recent studies about potatoes and high blood pressure, and results showing 6 best breads for people with heart disease.
The research was published in JAMA Network Open.
Copyright © 2026 Knowridge Science Report. All rights reserved.
